ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology


Business Summary

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2020 KRWUSD
Gross Profit469,262.42M397.71M
Operating income293,299.68M248.58M
Income before tax283,759.85M240.49M
Net income240,974.79M204.23M
Diluted EPS3,642.023.08
Dividends Per Share00
Total Assets6,424.20B5,913.83M
Total liabilities1,825.41B1,680.39M
Total equity4,598.78B4,233.43M
Operating cash flow202,090.02M171.27M
Currency in KRWCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 294,622.02M 464,629.33M 535,805.80M 701,591.85M 1,164.77B
Gross Profit 20,457.76M 122,304.94M 130,544.55M 230,536.76M 469,262.42M
Operating income -30,422.63M 65,979.40M 55,678.74M 92,084.47M 293,299.68M
Income before tax -101,678.33M -115,994.75M 302,975.83M 82,495.19M 283,759.85M
Net income -176,823.40M -96,972.11M 224,109.19M 202,904.09M 240,974.79M
EBITDA 29,727.25M 135,905.62M 147,129.29M 224,627.48M 436,474.55M
Diluted EPS -3,115 -1,466 3,387 3,066.63 3,642.02
Dividends Per Share 0 0 0 0 0
Total Assets 7,533.01B 7,183.09B 5,980.40B 5,911.62B 6,424.20B
Total liabilities 3,450.63B 3,206.64B 1,824.94B 1,557.17B 1,825.41B
Total equity 4,082.37B 3,976.45B 4,155.46B 4,354.45B 4,598.78B
Operating cash flow -62,661.29M 149,816.32M 36,787.30M 10,153.61M 202,090.02M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 253.94M 410.99M 486.86M 601.61M 987.19M
Gross Profit 17.63M 108.18M 118.62M 197.68M 397.71M
Operating income -26.22M 58.36M 50.59M 78.96M 248.58M
Income before tax -87.63M -102.60M 275.30M 70.73M 240.49M
Net income -152.40M -85.77M 203.63M 173.98M 204.23M
EBITDA 25.62M 120.21M 133.69M 192.61M 369.92M
Diluted EPS -2.68 -1.29 3.07 2.62 3.08
Dividends Per Share 0 0 0 0 0
Total Assets 6,236.97M 6,709.72M 5,359.74M 5,111.87M 5,913.83M
Total liabilities 2,856.96M 2,995.32M 1,635.54M 1,346.51M 1,680.39M
Total equity 3,380.01M 3,714.39M 3,724.20M 3,765.36M 4,233.43M
Operating cash flow -54.00M 132.52M 33.42M 8.70M 171.27M

Valuation Measures

Dec 2020
Operating margin25.18%
Profit margin20.68%

Key executives

  • President, Chief Executive Officer & Director: John Chongbo Rim
  • Managing Director & Head-Process Technology: Yong-Ho An
  • Head-Compliance Support: Hyung-Woo Moon
  • Executive Vice President: Kyu-Sung Lee
  • Senior Vice President: Ho-Yeol Yoon


  • Samsung C&T Corp. (43.4%)
  • Samsung Electronics Co., Ltd. (31.4%)
  • National Pension Service of Korea (5.1%)
  • Invesco Advisers, Inc. (1.7%)
  • BlackRock Fund Advisors (0.5%)
  • Samsung Asset Management Co., Ltd. (0.5%)
  • The Vanguard Group, Inc. (0.5%)
  • Norges Bank Investment Management (0.3%)
  • Fidelity Management & Research Co. LLC (0.2%)
  • Mirae Asset Global Investments Co., Ltd. (0.2%)

Contact Details

Related Companies

  • Samsung Biologics America, Inc.
  • Samsung BioLogics Co., Ltd. ESOA
  • Samsung Romania


  • Lonza Group AG
  • PanGen Biotech, Inc.
  • EirGenix Inc
  • Binex Co., Ltd
  • Celltrion, Inc.
  • Bukwang Pharmaceutical Co., Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • Greenwich LifeSciences, Inc.
  • Kodiak Sciences, Inc.
  • PharmAbcine Inc.
  • PharmGen Science, Inc.
  • Reyon Pharmaceutical Co., Ltd.
  • SK Chemicals Co., Ltd.
Last Updated on 26 Nov, 2021

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more